Frederic Gomez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6242573/publications.pdf

Version: 2024-02-01

47 papers 1,464 citations

361045 20 h-index 37 g-index

53 all docs 53 docs citations

53 times ranked

2022 citing authors

#	Article	IF	CITATIONS
1	Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain. Medicina ClÃnica, 2022, 158, 251-259.	0.3	7
2	Evaluation of five immunoassays and one lateral flow immunochromatography for anti-SARS-CoV-2 antibodies detection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, 40, 489-494.	0.3	2
3	Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. International Journal of Molecular Sciences, 2022, 23, 2202.	1.8	3
4	Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. Journal of Personalized Medicine, 2022, 12, 391.	1.1	12
5	Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain. Medicina ClÃnica (English Edition), 2022, 158, 251-259.	0.1	1
6	Prognostic Value of Procalcitonin and C-Reactive Protein in 1608 Critically III Patients with Severe Influenza Pneumonia. Antibiotics, 2021, 10, 350.	1.5	8
7	Usefulness of the antigen test for diagnosing SARS-CoV-2 infection in patients with and without symptoms. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 357-358.	0.2	1
8	Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015–2016. Vaccine, 2020, 38, 1170-1180.	1.7	11
9	Use of distinct antiâ€hypertensive drugs and risk for COVIDâ€19 among hypertensive people: A populationâ€based cohort study in Southern Catalonia, Spain. Journal of Clinical Hypertension, 2020, 22, 1379-1388.	1.0	35
10	Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open, 2020, 10, e041577.	0.8	29
11	Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. International Journal of Antimicrobial Agents, 2020, 56, 106026.	1.1	27
12	A Case of Aeromonas trota in an Immunocompromised Patient with Diarrhea. Microorganisms, 2020, 8, 399.	1.6	8
13	Incidence and Risk of Pneumococcal Pneumonia in Adults with Distinct Underlying Medical Conditions: A Population-Based Study. Lung, 2020, 198, 481-489.	1.4	7
14	Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes. International Journal of Antimicrobial Agents, 2020, 55, 105977.	1.1	33
15	The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine, 2018, 36, 7744-7752.	1.7	36
16	Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study. BMC Infectious Diseases, 2018, 18, 196.	1.3	18
17	Molecular Characterization of Fluoroquinolone-Resistant <i>Haemophilus parainfluenzae</i> Clinical Isolates in Spain. Microbial Drug Resistance, 2017, 23, 935-939.	0.9	4
18	Antimicrobial susceptibility, virulence potential and sequence types associated with Arcobacter strains recovered from human faeces. Journal of Medical Microbiology, 2017, 66, 1736-1743.	0.7	18

#	Article	lF	CITATIONS
19	Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Critical Care, 2016, 20, 149.	2.5	83
20	Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. Infection, 2015, 43, 699-706.	2.3	20
21	Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007–2013: Incidence, serotype distribution and vaccine's effectiveness. International Journal of Pediatric Otorhinolaryngology, 2015, 79, 2104-2108.	0.4	15
22	Association between C-Reactive Protein Rapid Test and Group A Streptococcus Infection in Acute Pharyngitis. Journal of the American Board of Family Medicine, 2014, 27, 424-426.	0.8	17
23	Genetic and Kinetic Characterization of the Novel AmpC \hat{l}^2 -Lactamases DHA-6 and DHA-7. Antimicrobial Agents and Chemotherapy, 2014, 58, 6544-6549.	1.4	7
24	Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged >=60 Years: 3 Years of Follow-up in the CAPAMIS Study. Clinical Infectious Diseases, 2014, 58, 909-917.	2.9	129
25	A severe case of persistent diarrhoea associated with Arcobacter cryaerophilus but attributed to Campylobacter sp. and a review of the clinical incidence of Arcobacter spp. New Microbes and New Infections, 2014, 2, 31-37.	0.8	93
26	Incidence of pneumococcal infections among children under 15Âyears in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002–2009. Infection, 2013, 41, 439-446.	2.3	6
27	Validity of a point-of-care based on heterophile antibody detection for the diagnosis of infectious mononucleosis in primary care. European Journal of General Practice, 2012, 18, 15-21.	0.9	3
28	Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. BMC Public Health, 2012, 12, 222.	1.2	41
29	Invasive pneumococcal disease in Catalonian elderly people, 2002–2009: Serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era. Vaccine, 2011, 29, 7430-7434.	1.7	9
30	Effect of Antibiotic Diversity on Ventilator-Associated Pneumonia Caused by ESKAPE Organisms. Chest, 2011, 140, 643-651.	0.4	52
31	Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients. Current Pharmaceutical Design, 2010, 16, 3379-3389.	0.9	12
32	Microscopic Image of the Protoscolex of Echinococcus granulosus on the "Hydatid Sand― American Journal of Tropical Medicine and Hygiene, 2010, 82, 980-980.	0.6	0
33	A Randomized Trial of Dental Brushing for Preventing Ventilator-Associated Pneumonia. Chest, 2009, 136, 433-439.	0.4	98
34	Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia. BMC Infectious Diseases, 2009, 9, 36.	1.3	17
35	Repetition of the rapid antigen test in initially negative supposed streptococcal pharyngitis is not necessary in adults. International Journal of Clinical Practice, 2009, 63, 1340-1344.	0.8	9
36	Epidemiology of community-acquired pneumonia in older adults: A population-based study. Respiratory Medicine, 2009, 103, 309-316.	1.3	164

#	Article	IF	CITATIONS
37	Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case–control study. Vaccine, 2009, 27, 1504-1510.	1.7	82
38	Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: Results of the EVAN-65 study. Vaccine, 2008, 26, 1955-1962.	1.7	35
39	Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia*. Critical Care Medicine, 2007, 35, 2064-2070.	0.4	109
40	Clinical Characteristics and Outcome of Infective Endocarditis in Individuals of the General Population Managed at a Teaching Hospital Without Cardiac Surgery Facilities. Study of 120 Cases. Revista Espanola De Cardiologia (English Ed), 2006, 59, 1131-1139.	0.4	4
41	Risk Factors for Ventilator-associated Pneumonia by Pseudomonas aeruginosa in Presence of Recent Antibiotic Exposure. Anesthesiology, 2006, 105, 709-714.	1.3	47
42	Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. Clinical Biochemistry, 2003, 36, 129-134.	0.8	14
43	Differences between Genotyping and Phenotyping Methods for Assessing Apolipoprotein(a) Size Polymorphisms. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1340-4.	1.4	0
44	Impaired vitamin E status in patients with parenchymal liver cirrhosis: Relationships with lipoprotein compositional alterations, nutritional factors, and oxidative susceptibility of plasma. Metabolism: Clinical and Experimental, 2002, 51, 609-615.	1.5	18
45	Plasma Homocysteine Concentrations in Patients with Liver Cirrhosis. Clinical Chemistry, 2002, 48, 183-185.	1.5	19
46	Evaluation of a particle-enhanced turbidimetric immunoassay for the measurement of ferritin: application to patients participating in an autologous blood transfusion program. Clinical Biochemistry, 2000, 33, 191-196.	0.8	21
47	Agreement Study of Methods Based on the Elimination Principle for the Measurement of LDL- and HDL-Cholesterol Compared with Ultracentrifugation in Patients with Liver Cirrhosis. Clinical Chemistry, 2000, 46, 1188-1191.	1.5	20